Literature DB >> 27186408

Association of CYP8A1 (Prostacyclin I2 synthase) polymorphism rs5602 with breast cancer in Mexican woman.

Eduardo Beltran-Sarmiento1, Esaú Floriano-Sánchez2, Cindy Bandala3, Eleazar Lara-Padilla1, Noemí Cárdenas-Rodríguez4.   

Abstract

Breast cancer (BCa) is the most common cancer in Mexican women. Certain risk factors, such as environmental and lifestyle factors have been implicated in BCa initiation and progression. Moreover, genetic factors, such as single nucleotide polymorphisms (SNPs) of the P450 system, have been reported in BCa. In this report, and for the first time in the literature, we analyzed the rs5602 (67730 T > C) polymorphism in the CYP8A1 in patients with BCa and in healthy Mexican women to identify a potential risk between this polymorphism and BCa. Leukocyte cells from 38 control patients and tissue from radical mastectomy surgeries in 64 BCa patients were used for polymorphism analysis using an allelic discrimination assay with TaqMan probes. Links with clinic-pathological characteristics were also analyzed. Statistical analysis was performed using the standard χ(2) or Fisher exact test statistic. All CYP8A1 genotypes were detected in patients with BCa and the controls. Significant differences were observed in the distribution of CYP8A1 genotypes between the patients and controls (P=0.0008) and allele C was significantly associated with BCa risk (OR 2.08, 95% CI 1.166-3.72, P=0.0178). All polymorphism frequencies were in Hardy-Weinberg Equilibrium (HWE) in the controls (P > 0.05). We found that variant 67730 T > C was significantly associated with an increased risk of BCa (P < 0.05). We not observed an association of the TT and TC + CC genotypes with the clinical stage, BIRADS, estrogen receptor (ER) status, progesterone receptor (PR) status, HER2 status, p53 status, CD34 status, metastasis or therapy use. These results indicate that the CYP8A1 rs5602 SNP is a possible risk factor for BCa in Mexican women. This study showed an association between the CYP8A1 polymorphism and BCa risk in a Mexican population.

Entities:  

Keywords:  Cytochrome P450 8A1; Mexican women; breast cancer; polymorphism

Year:  2016        PMID: 27186408      PMCID: PMC4859665     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  40 in total

1.  Age of natural menopause among women in Mexico City.

Authors:  F Garrido-Latorre; E C Lazcano-Ponce; L López-Carrillo; M Hernández-Avila
Journal:  Int J Gynaecol Obstet       Date:  1996-05       Impact factor: 3.561

2.  Reproductive and lifestyle risk factors and mammographic density in Mexican women.

Authors:  Megan S Rice; Kimberly A Bertrand; Martin Lajous; Rulla M Tamimi; Gabriela Torres; Ruy López-Ridaura; Isabelle Romieu
Journal:  Ann Epidemiol       Date:  2015-08-29       Impact factor: 3.797

Review 3.  Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins.

Authors:  F J Gonzalez; H V Gelboin
Journal:  Drug Metab Rev       Date:  1994       Impact factor: 4.518

Review 4.  Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer.

Authors:  J A Williams; D H Phillips
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

Review 5.  The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.

Authors:  K T Kivistö; H K Kroemer; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

6.  Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model.

Authors:  Robert S Stearman; Lori Dwyer-Nield; Laura Zerbe; Stacy A Blaine; Zeng Chan; Paul A Bunn; Gary L Johnson; Fred R Hirsch; Daniel T Merrick; Wilbur A Franklin; Anna E Baron; Robert L Keith; Raphael A Nemenoff; Alvin M Malkinson; Mark W Geraci
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

7.  Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer.

Authors:  Robert L Keith; York E Miller; Yasushi Hoshikawa; Mark D Moore; Tracy L Gesell; Bifeng Gao; Alvin M Malkinson; Heiko A Golpon; Raphael A Nemenoff; Mark W Geraci
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

Review 8.  The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer.

Authors:  Mary-Clare Cathcart; John V Reynolds; Kenneth J O'Byrne; Graham P Pidgeon
Journal:  Biochim Biophys Acta       Date:  2010-02-01

9.  Human gene encoding prostacyclin synthase (PTGIS): genomic organization, chromosomal localization, and promoter activity.

Authors:  C Yokoyama; T Yabuki; H Inoue; Y Tone; S Hara; T Hatae; M Nagata; E I Takahashi; T Tanabe
Journal:  Genomics       Date:  1996-09-01       Impact factor: 5.736

Review 10.  A novel pathway of prostacyclin signaling-hanging out with nuclear receptors.

Authors:  Hyunjung Lim; Sudhansu K Dey
Journal:  Endocrinology       Date:  2002-09       Impact factor: 4.736

View more
  3 in total

Review 1.  Prostaglandin terminal synthases as novel therapeutic targets.

Authors:  Shuntaro Hara
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2017       Impact factor: 3.493

2.  Interactions between RASA2, CADM1, HIF1AN gene polymorphisms and body fatness with breast cancer: a population-based case-control study in China.

Authors:  Zheng Zhu; Zhimei Teng; Fränzel J B van Duijnhoven; Meihua Dong; Yun Qian; Hao Yu; Jie Yang; Renqiang Han; Jian Su; Wencong Du; Xingyu Huang; Jinyi Zhou; Xiaojin Yu; Ellen Kampman; Ming Wu
Journal:  Oncotarget       Date:  2017-10-05

3.  Genetic variants of PTGS2, TXA2R and TXAS1 are associated with carotid plaque vulnerability, platelet activation and TXA2 levels in ischemic stroke patients.

Authors:  Xingyang Yi; Jing Lin; Hua Luo; Chun Wang; Yingying Liu
Journal:  PLoS One       Date:  2017-07-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.